MRKMerck Sharp & Dohme LLCRunning, no new patients
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Urinary Bladder Neoplasms
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 520 (planned)
- Started
- May 19, 2020
- Main results expected
- Jan 31, 2027
- Fully finished
- Nov 1, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Bladder Intact Event-Free Survival (BI-EFS)
Measured over: Up to approximately 76 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04241185 · record last updated 2026-05-01 · checked 2026-11-09 15:47 UTC